ZTS Zoetis Earnings and EPS analysis

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 90

EPS in 2026 (TTM): $5.89

Last Report Period Date: Sep 30, 2026

As of November 2026, ZTS's trailing twelve months (TTM) EPS stands at $5.89, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $6.03, which represents an increase compared to its EPS of $5.47 in 2024. ZTS reported an EPS of $1.44 for the quarterly report ending on Sep 30, 2026.

ZTS earnings history

Historical annual and quarterly earnings per share (EPS) data for Zoetis
EPS (TTM)
$5.89
EPS Growth YoY (Quarterly)
-11.7%
EPS (Quarterly)
$1.44
EPS Growth (Quarterly)
-12.7%

For 2025, Zoetis's EPS was $6.03, an increase of 10.2% from $5.47 in 2024. For the quarter ending Sep 30, 2026, the EPS was $1.44, showing a 11.7% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2026 is $5.89. In 2024, the annual EPS was $5.47, showing an increase of 7.7% from 2023.

ZTS EPS vs price chart

ZTS EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-11.7%
EPS growth YoY
10.2%
EPS growth 3Y avg
10.2%
EPS growth 5Y avg
11.9%

Zoetis has recorded a decrease in EPS of 11.7% over the last 12 months (YoY, quarterly). For the last three years, ZTS recorded an average annual EPS growth rate of 10.2%. Zoetis had an average annual EPS growth rate of 11.9% over the last 5 years. Across the last decade, ZTS had an average annual EPS growth of 24.4%.

ZTS Earnings Waterfall

Breakdown of revenue, profit and net income for Zoetis

ZTS Earnings vs Peers

What are the earnings of ZTS compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
PAHC Phibro Animal Health Corp 13.79 106.7% 44.8% 12.9%
ZTS Zoetis Inc - Class A 14.33 10.2% 10.2% 11.9%
PFE Pfizer Inc 40.65 -3.5% -37.4% -3.7%
LLY Lilly(Eli) & Company 46.41 95.6% 49.2% 27.5%
ICCC Immucell Corp 60.11 53.8% N/A N/A
MRK Merck & Co Inc 144.46 8% 8.4% 21.2%

All data is based on quarterly TTM periods, unless otherwise specified.